DNA Origami-Cyanine Nanocomplex for Precision Imaging of KRAS-Mutant Pancreatic Cancer Cells.
Selective delivery of imaging agents to pancreatic cancer cells (PCCs) within the highly desmoplastic tumors of pancreatic ductal adenocarcinoma (PDAC) represents a significant advancement.
APA
Moon HR, Du Y, et al. (2025). DNA Origami-Cyanine Nanocomplex for Precision Imaging of KRAS-Mutant Pancreatic Cancer Cells.. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(19), e2410278. https://doi.org/10.1002/advs.202410278
MLA
Moon HR, et al.. "DNA Origami-Cyanine Nanocomplex for Precision Imaging of KRAS-Mutant Pancreatic Cancer Cells.." Advanced science (Weinheim, Baden-Wurttemberg, Germany), vol. 12, no. 19, 2025, pp. e2410278.
PMID
39951277
Abstract
Selective delivery of imaging agents to pancreatic cancer cells (PCCs) within the highly desmoplastic tumors of pancreatic ductal adenocarcinoma (PDAC) represents a significant advancement. This approach allows for precise labeling of PCCs while excluding cancer-associated fibroblasts (CAFs), thereby enhancing both research and diagnostic capabilities. Additionally, it holds the potential to target and eliminate PCCs precisely without harming the surrounding stromal cells in the PDAC tumor microenvironment (TME). In this study, DNA origami-cyanine (Do-Cy) nanocomplexes are synthesized to image KRAS-mutant PCCs selectively in the PDAC TME. These Do-Cy nanocomplexes are hypothesized to be internalized preferentially to KRAS-mutant PCCs over CAFs via elevated macropinocytosis. Several designs of Do-Cy nanocomplexes are synthesized and characterized their cellular uptake using both engineered in vitro and xenograft pancreatic cancer models. The results are further discussed for the implication of precision delivery of therapeutic and imaging agents to KRAS-mutant cancers.
MeSH Terms
Pancreatic Neoplasms; Humans; Proto-Oncogene Proteins p21(ras); Animals; Mice; Cell Line, Tumor; Carcinoma, Pancreatic Ductal; DNA; Tumor Microenvironment; Mutation; Carbocyanines